drugset / Trial / NCT04318210
Open Label Extension (OLE) of the TDF2 Study, Botswana
Completed
229 enrolled
Centers for Disease Control and Prevention
Botswana Ministry of Health · collab
NaSingle-groupOpen-labelPrevention
Summary
This study is an open label and is an extension to the TDF2 study in which the investigators offered daily oral tenofovir/emtricitabine (TDF/FTC) for a maximum of 12 months to HIV uninfected former participants of the TDF2 study.
Timeline
- Start
- 2012-10
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |
| Subject | emtricitabine | Other / unclassified | 200 mg | Oral |